HUMAN GENOME SCIENCES INC.
BiotechHUMAN GENOME SCIENCES INC. is a biotechnology company focused on Immunology, Oncology, Gastroenterology.
HUMAN GENOME SCIENCES INC. at a Glance
- Fast trial execution (16 months median completion)
HUMAN GENOME SCIENCES INC.'s Key Drugs
HUMAN GENOME SCIENCES INC.'s core commercial portfolio centers on BENLYSTA, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
HUMAN GENOME SCIENCES INC.'s Recent FDA Approvals
New NDA/BLA approvals for HUMAN GENOME SCIENCES INC. over the last two years — novel drugs only, excluding generics and label supplements.
HUMAN GENOME SCIENCES INC.'s Therapeutic Areas
HUMAN GENOME SCIENCES INC.'s approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HUMAN GENOME SCIENCES INC.'s Top Competitors
HUMAN GENOME SCIENCES INC.'s closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HUMAN GENOME SCIENCES INC. Pipeline Snapshot
HUMAN GENOME SCIENCES INC. has 13 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 1 Phase 2 and 8 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BENLYSTA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/1 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2011-03-09
- Latest
- 2025-06-20
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges